Сравнение

Icatibant vs. Lanreotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

138614-30-9

108736-35-2

Молекулярная масса

1304.52 g/mol

1096.34 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Icatibant	Lanreotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Icatibant and Lanreotid?: Icatibant is classified as "Исследования (прочее)", while Lanreotid is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Lanreotid?: The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Lanreotid in Germany and the United States?: Германия: Icatibant — Рецептурный, Lanreotid — Рецептурный. США: Icatibant — Рецептурный, Lanreotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Lanreotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Icatibant and Lanreotid?

Icatibant is classified as "Исследования (прочее)", while Lanreotid is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Lanreotid?

The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Lanreotid in Germany and the United States?

Германия: Icatibant — Рецептурный, Lanreotid — Рецептурный. США: Icatibant — Рецептурный, Lanreotid — Рецептурный. These are factual summaries with source and review date on the individual pages.